NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC

ROS1 fusion-positive NSCLC

Panel discussion

Managing ROS1 fusion-positive NSCLC in Europe and the USA

Luis Paz-Ares leads Jaime Schneider and Benjamin Besse in a discussion on the management of patients with ROS1 fusion-positive NSCLC in 2022.

ALK fusion-positive NSCLC

Panel discussion

ALK fusion-positive NSCLC: International approaches to management

Ross Camidge leads Rosario García Campelo and Yongchang Zhang in a discussion on the detection and treatment of ALK fusion-positive NSCLC in 2022.

Interview

Pathologic testing for ALK and ROS1 aberrations in NSCLC

Frédérique Penault-Llorca outlines the importance of the ALK and ROS1 driver alterations in NSCLC and the available methods for their detection.

RET fusion-positive NSCLC

Panel discussion

RET fusion-positive NSCLC: Delivering targeted treatment

Stephen Liu leads Melina Marmarelis and Vivek Subbiah in a discussion on the care of patients with RET fusion-positive NSCLC in light of the ARROW trial of pralsetinib.

Interview

ARROW points the way for RET fusion-positive NSCLC treatment

Stephen Liu outlines the ARROW study design and findings and discusses the impact of pralsetinib on the care of patients with treatment-naïve and previously treated NSCLC positive for a RET fusion

Funding and disclaimer

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Medicine Matters Oncology

NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC

ROS1 fusion-positive NSCLC

Managing ROS1 fusion-positive NSCLC in Europe and the USA

ALK fusion-positive NSCLC

ALK fusion-positive NSCLC: International approaches to management

Pathologic testing for ALK and ROS1 aberrations in NSCLC

RET fusion-positive NSCLC

RET fusion-positive NSCLC: Delivering targeted treatment

ARROW points the way for RET fusion-positive NSCLC treatment

Funding and disclaimer

Attention: This content is intended for healthcare professionals only